Nowadays, the term identifies the simultaneous use of aspirin and a P2Y12 inhibitor (P2Y12i), a cornerstone in the treatment of acute coronary syndromes (ACS) [1,2]. This evidence concerns the gene P2RY12 and acute coronary syndrome.